BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 33795829)

  • 1. Description of the genetic variants identified in a cohort of patients diagnosed with localized anal squamous cell carcinoma and treated with panitumumab.
    Trilla-Fuertes L; Gámez-Pozo A; Maurel J; Garcia-Carbonero R; Capdevila J; G-Pastrián L; Mendiola M; Peña C; López-Vacas R; Cuatrecasas M; García-Alfonso P; Ramos-Ruiz R; Llorens C; Ghanem I; Conill C; Heredia-Soto V; Campos-Barros Á; Fresno Vara JÁ; Feliu J
    Sci Rep; 2021 Apr; 11(1):7402. PubMed ID: 33795829
    [TBL] [Abstract][Full Text] [Related]  

  • 2. VITAL phase 2 study: Upfront 5-fluorouracil, mitomycin-C, panitumumab and radiotherapy treatment in nonmetastatic squamous cell carcinomas of the anal canal (GEMCAD 09-02).
    Feliu J; Garcia-Carbonero R; Capdevila J; Guasch I; Alonso-Orduna V; Lopez C; Garcia-Alfonso P; Castanon C; Sevilla I; Cerezo L; Conill C; Quintana-Angel B; Sanchez ME; Ghanem I; Martin-Richard M; Lopez-Gomez M; Leon A; Caro M; Fernandez T; Maurel J
    Cancer Med; 2020 Feb; 9(3):1008-1016. PubMed ID: 31851776
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Malignant tumors of the anal canal: the spectrum of disease, treatment, and outcomes.
    Klas JV; Rothenberger DA; Wong WD; Madoff RD
    Cancer; 1999 Apr; 85(8):1686-93. PubMed ID: 10223561
    [TBL] [Abstract][Full Text] [Related]  

  • 4. FOLFCIS Treatment and Genomic Correlates of Response in Advanced Anal Squamous Cell Cancer.
    Mondaca S; Chatila WK; Bates D; Hechtman JF; Cercek A; Segal NH; Stadler ZK; Varghese AM; Kundra R; Capanu M; Shia J; Schultz N; Saltz L; Yaeger R
    Clin Colorectal Cancer; 2019 Mar; 18(1):e39-e52. PubMed ID: 30316684
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Utility of CYP2D6 copy number variants as prognostic biomarker in localized anal squamous cell carcinoma.
    Trilla-Fuertes L; Gámez-Pozo A; Nogué M; Busquier I; Arias F; López-Campos F; Fernández-Montes A; Ruiz A; Velázquez C; Martín-Bravo C; Pérez-Ruiz E; Asensio E; Hernández-Yagüe X; Rodrigues A; Ghanem I; López-Vacas R; Hafez A; Arias P; Dapía I; Solís M; Dittmann A; Ramos R; Llorens C; Maurel J; Campos-Barros Á; Fresno Vara JÁ; Feliu J
    Cancer; 2023 Aug; 129(16):2581-2592. PubMed ID: 37096763
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Epidermoid carcinomas of anal canal treated with radiation therapy and concomitant chemotherapy (5-fluorouracil and cisplatin)].
    Deniaud-Alexandre E; Touboul E; Tiret E; Sezeur A; Hannoun L; Houry S; Huguet F; Pène F; Parc R; Schlienger M
    Cancer Radiother; 2006 Dec; 10(8):572-82. PubMed ID: 17110148
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tumor site predicts outcome after radiochemotherapy in squamous-cell carcinoma of the anal region: long-term results of 101 patients.
    Grabenbauer GG; Kessler H; Matzel KE; Sauer R; Hohenberger W; Schneider IH
    Dis Colon Rectum; 2005 Sep; 48(9):1742-51. PubMed ID: 15991058
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cisplatin and fluorouracil with or without panitumumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck (SPECTRUM): an open-label phase 3 randomised trial.
    Vermorken JB; Stöhlmacher-Williams J; Davidenko I; Licitra L; Winquist E; Villanueva C; Foa P; Rottey S; Skladowski K; Tahara M; Pai VR; Faivre S; Blajman CR; Forastiere AA; Stein BN; Oliner KS; Pan Z; Bach BA;
    Lancet Oncol; 2013 Jul; 14(8):697-710. PubMed ID: 23746666
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Concurrent cisplatin, continuous infusion fluorouracil and radiotherapy followed by tailored consolidation treatment in non metastatic anal squamous cell carcinoma.
    Zampino MG; Magni E; Leonardi MC; Santoro L; Petazzi E; Fodor C; Petralia G; Trovato C; Nolè F; Orecchia R
    BMC Cancer; 2011 Feb; 11():55. PubMed ID: 21291546
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Outcome of simultaneous radiochemotherapy of anal carcinoma].
    Fraunholz IB; Adamietz IA; Lorenz M; Staib-Sebler E; Böttcher HD
    Zentralbl Chir; 1997; 122(1):39-43. PubMed ID: 9133135
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic role of p53 protein expression in epidermoid carcinoma of the anal canal.
    Wong CS; Tsao MS; Sharma V; Chapman WB; Pintilie M; Cummings BJ
    Int J Radiat Oncol Biol Phys; 1999 Sep; 45(2):309-14. PubMed ID: 10487550
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Prognosis of epidermoid anal carcinoma regression after conservative treatment].
    Vorob'ëv GI; Odariuk TS; Orlova LP; Nechushkin MI; Rybakov EG
    Vopr Onkol; 2004; 50(6):663-7. PubMed ID: 15755059
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of anal canal carcinoma with high dose radiation therapy and concomitant fluorouracil-cisplatinum. Long-term results in 95 patients.
    Gerard JP; Ayzac L; Hun D; Romestaing P; Coquard R; Ardiet JM; Mornex F
    Radiother Oncol; 1998 Mar; 46(3):249-56. PubMed ID: 9572617
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Docetaxel, cisplatin, and fluorouracil chemotherapy for metastatic or unresectable locally recurrent anal squamous cell carcinoma (Epitopes-HPV02): a multicentre, single-arm, phase 2 study.
    Kim S; François E; André T; Samalin E; Jary M; El Hajbi F; Baba-Hamed N; Pernot S; Kaminsky MC; Bouché O; Desrame J; Zoubir M; Ghiringhelli F; Parzy A; De La Fouchardiere C; Smith D; Deberne M; Spehner L; Badet N; Adotevi O; Anota A; Meurisse A; Vernerey D; Taieb J; Vendrely V; Buecher B; Borg C
    Lancet Oncol; 2018 Aug; 19(8):1094-1106. PubMed ID: 30042063
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Epidermoid anal cancer: results from the UKCCCR randomised trial of radiotherapy alone versus radiotherapy, 5-fluorouracil, and mitomycin. UKCCCR Anal Cancer Trial Working Party. UK Co-ordinating Committee on Cancer Research.
    Lancet; 1996 Oct; 348(9034):1049-54. PubMed ID: 8874455
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sphincter preservation with chemoradiation in anal canal carcinoma: abdominoperineal resection in selected cases?
    Grabenbauer GG; Matzel KE; Schneider IH; Meyer M; Wittekind C; Matsche B; Hohenberger W; Sauer R
    Dis Colon Rectum; 1998 Apr; 41(4):441-50. PubMed ID: 9559628
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Radiochemotherapy for anal carcinoma - effectivity and late toxicity.
    Mai SK; Grieger J; Lachmann R; Bohrer M; Tiefenbacher U; Wenz F
    Onkologie; 2002 Feb; 25(1):55-9. PubMed ID: 11893884
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Outcomes with anti-EGFR monoclonal antibodies in metastatic and recurrent anal squamous cell carcinoma.
    Rogers JE; Jácome AAA; Ohinata A; Wolff R; Morris VK; Johnson B; Mehdizadeh A; Rothschild ND; Ahmed SU; Guerra JL; Eng C
    Expert Rev Anticancer Ther; 2020 Oct; 20(10):901-908. PubMed ID: 32799569
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Outcomes of chemoradiotherapy with 5-Fluorouracil and mitomycin C for anal cancer in immunocompetent versus immunodeficient patients.
    Seo Y; Kinsella MT; Reynolds HL; Chipman G; Remick SC; Kinsella TJ
    Int J Radiat Oncol Biol Phys; 2009 Sep; 75(1):143-9. PubMed ID: 19203845
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Advanced anal squamous cell carcinoma -- radiotherapy or surgery?
    Smigielski J; Rychter A; Fijuth J; Brocki M
    Chirurgia (Bucur); 2012; 107(5):626-30. PubMed ID: 23116837
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.